Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Modality
Small molecule
Development Phase
Unknown
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06532149CT.gov ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypogonadism, Male
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Brigatinib (this asset) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Unk | D · 30 |
| Testosterone Undecylate | University of Sao Paulo General Hospital | P4 | BB |
| Testosterone Enantate | Tulane University | P4 | BB |
| Testosterone Cipionate | University of Miami | P4 | B |
| Clomiphene Citrate | University of Sao Paulo | P2 | B |
| Recombinant Ephb4-Hsa Fusion Protein | Northwestern University | P2 | CCC |
| Dabrafenib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Unk | D |
| Sotorasib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Unk | D |
| Lorlatinib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Unk | D |
+9 more in the Hypogonadism, Male cohort
Other indications for Brigatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer | — | P3 | B · 63 |
| Non-Small Cell Lung Carcinoma | — | P3 | B · 60 |
| Hepatocellular Carcinoma | — | P3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Brigatinib in Hypogonadism, Male. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/brigatinib-hypogonadism-male
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →